Plasma hepatocyte growth factor elevation may be associated with early metastatic disease in primary lung cancer patients

Annals of Thoracic and Cardiovascular Surgery

Volumn 18, Issue 1, 2012, Pages 1-7

  Hosoda, Hiroshi ^a   Izumi, Hiroyuki ^a   Tukada, Yoshikazu ^a   Takagiwa, Jun ^a   Chiaki, Tomoshige ^a   Yano, Makoto ^b   Arai, Hirokuni ^c  

^a Hokushin General Hospital   (Japan)

^b MUSASHINO RED CROSS HOSPITAL   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

C met; Hepatocyte growth factor; Non small cell lung cancer

Indexed keywords

SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TUMOR MARKER;

AGED; ARTICLE; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; METASTASIS; NONPARAMETRIC TEST; PATHOLOGY; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL MODEL; SURVIVAL;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HEPATOCYTE GROWTH FACTOR; HUMANS; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; NEOPLASM METASTASIS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; ROC CURVE; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84857466158     PISSN: 13411098     EISSN: None     Source Type: Journal    
DOI: 10.5761/atcs.oa.09.01522     Document Type: Article

References (28)

1. Siegfried JM, Weissfeld LA, Singh-Kaw P, et al. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer. Cancer Res 1997; 57: 433-9.
2. Olivero M, Rizzo M, Madeddu R, et al. Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br J Cancer 1996; 74: 1862-8.
3. Takanami I, Tanana F, Hashizume T, et al. Hepatocyte growth factor and c-Met/hepatocyte growth factor receptor in pulmonary adenocarcinomas: an evaluation of their expression as prognostic markers. Oncology 1996; 53: 392-7.
4. Singh-Kaw P, Zarnegar R, Siegfried JM. Stimulatory effects of hepatocyte growth factor on normal and neoplastic human bronchial epithelial cells. Am J Physiol 1995; 268: L1012-20.
5. Yamashita J, Ogawa M, Nakano S, et al. High levels of hepatocyte growth factor/scatter factor in diffuse-type bronchioloalveolar cell carcinoma. Cancer 1998; 83: 2091-8.
6. Tsao MS, Yang Y, Marcus A, et al. Hepatocyte growth factor is predominantly expressed by the carcinoma cells in non-small-cell lung cancer. Hum Pathol 2001; 32: 57-65.
7. Yi S, Chen JR, Viallet J, et al. Paracrine effects of hepatocyte growth factor/scatter factor on non-small-cell lung carcinoma cell lines. Br J Cancer 1998; 77: 2162-70.
8. Zarnegar R, Michalopoulos GK. The many faces of hepatocyte growth factor: from hepatopoiesis to hematopoiesis. J Cell Biol 1995; 129: 1177-80.
9. Birchmeier C, Gherardi E. Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol 1998; 8: 404-10.
10. Bredin CG, Liu Z, Hauzenberger D, et al. Growth-factor-dependent migration of human lung-cancer cells. Int J Cancer 1999; 82: 338-45.
11. Sakon M, Kita Y, Yoshida T, et al. Plasma hepatocyte growth factor levels are increased in systemic inflammatory response syndrome. Surg Today 1996; 26: 236-41.
12. Tomiya T, Tani M, Yamada S, et al. Serum hepatocyte growth factor levels in hepatectomized and nonhepatectomized surgical patients. Gastroenterology 1992; 103: 1621-4.
13. Ueda T, Takeyama Y, Toyokawa A, et al. Significant elevation of serum human hepatocyte growth factor levels in patients with acute pancreatitis. Pancreas 1996; 12: 76-83.
14. To Y, Dohi M, Matsumoto K, et al. A two-way interaction between hepatocyte growth factor and interleukin-6 in tissue invasion of lung cancer cell line. Am J Respir Cell Mol Biol 2002; 27: 220-6.
15. Shimomura T, Kondo J, Ochiai M, et al. Activation of the zymogen of hepatocyte growth factor activator by thrombin. J Biol Chem 1993; 268: 22927-32.
16. Webb CP, Taylor GA, Jeffers M, et al. Evidence for a role of Met-HGF/SF during Ras-mediated tumorigenesis/metastasis. Oncogene 1998; 17: 2019-25.
17. Weiss L. Metastatic inefficiency. Adv Cancer Res 1990; 54: 159-211.
18. Heiss MM, Allgayer H, Gruetzner KU, et al. dividual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nat Med 1995; 1: 1035-9.
19. Lindemann F, Schlimok G, Dirschedl P, et al. Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet 1992; 340: 685-9.
20. Ghossein RA, Bhattacharya S, Rosai J. Molecular detection of micrometastases and circulating tumor cells in solid tumors. Clin Cancer Res 1999; 5: 1950-60.
21. Mori M, Mimori K, Ueo H, et al. Molecular detection of circulating solid carcinoma cells in the peripheral blood: the concept of early systemic disease. Int J Cancer 1996; 68: 739-43.
22. Moss TJ, Sanders DG. Detection of neuroblastoma cells in blood. J Clin Oncol 1990; 8: 736-40.
23. Stahel RA, Mabry M, Skarin AT, et al. Detection of bone marrow metastasis in small-cell lung cancer by monoclonal antibody. J Clin Oncol 1985; 3: 455-61.
24. Glaves D, Huben RP, Weiss L. Haematogenous dissemination of cells from human renal adenocarcinomas. Br J Cancer 1988; 57: 32-5.
25. Bogden AE, Moreau JP, Eden PA. Proliferative response of human and animal tumours to surgical wounding of normal tissues: onset, duration and inhibition. Br J Cancer 1997; 75: 1021-7.
26. Pilewski JM, Bumbalo TS 3rd, Davis AG, et al. Hepatocyte growth factor promotes tumor growth in a novel in vivo model of human lung cancer. Am J Respir Cell Mol Biol 2001; 24: 556-62.
27. Jiang WG, Martin TA, Parr C, et al. Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit Rev Oncol Hematol 2005; 53: 35-69.
28. Matsumoto K, Nakamura T. NK4 (HGF-antagonist/ angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci 2003; 94: 321-7.